FGFR1 and pancreatic neoplasm: In the FIGHT-101 clinical trial, one of five patients with pancreatic cancer showed a partial response to anti-FGFR1-3 treatment (pemigatinib); this case was positive for FGFR2::USP33 fusion [31].